GRAIL Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
910
- Stock Symbol
-
GRAL
- Investments
-
3
- Share Price
-
$115.89
- (As of Friday Closing)
GRAIL General Information
Description
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Contact Information
Website
www.grail.comCorporate Office
- 1525 O'Brien Drive
- Menlo Park, CA 94025
- United States
Corporate Office
- 1525 O'Brien Drive
- Menlo Park, CA 94025
- United States
GRAIL Timeline
GRAIL Stock Performance
As of 13-Nov-2026, GRAIL’s stock price is $115.89. Its current market cap is $5.21B with 45M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $115.89 | $121.35 | $41.50 - $166.47 | $5.21B | 45M | 1.05M | -$9.28 |
GRAIL Financials Summary
As of 30-Sep-2026, GRAIL has a trailing 12-month revenue of $167M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,488,333 | 2,854,948 | (181,586) | |
| Revenue | 166,604 | 147,172 | 125,595 | 93,105 |
| EBITDA | (424,221) | (406,812) | (2,031,038) | (1,356,893) |
| Net Income | (406,178) | (408,351) | (2,027,005) | (1,465,685) |
| Total Assets | 2,730,562 | 2,922,015 | 2,983,307 | 3,913,814 |
| Total Debt | 85,848 | 54,863 | 68,141 | 84,407 |
GRAIL Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GRAIL Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
GRAIL Comparisons
Industry
Financing
Details
GRAIL Competitors (22)
One of GRAIL’s 22 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| GeneCast Biotechnology | Private Equity-Backed | Wuxi, China | ||||
| Agomab Therapeutics | Formerly VC-backed | Antwerp, Belgium | ||||
| Fore Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Cardiff Oncology | Formerly Angel backed | San Diego, CA |
GRAIL Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
GRAIL Patents
GRAIL Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026170036-A1 | Augmented training of a cell-free dna cancer classifier with white blood cell dna | Pending | 06-Feb-2025 | ||
| WO-2026161757-A1 | Multimodal sample swap detection and remediation | Pending | 27-Jan-2025 | ||
| EP-4837040-A1 | Rapid bisulfite conversion and recovery of nucleic acid molecules | Pending | 30-Dec-2024 | ||
| WO-2026136616-A1 | Systems and methods for classifier retraining for sub-populations with unique epigenetic patterns | Pending | 19-Dec-2024 | ||
| WO-2026136615-A1 | Systems and methods for determining cancer progression | Pending | 19-Dec-2024 | G16B20/00 |
GRAIL Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
GRAIL Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
GRAIL Investments & Acquisitions (3)
GRAIL’s most recent deal was a Seed Round with Youmio for . The deal was made on 05-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Youmio | 05-Apr-2024 | Seed Round | Entertainment Software | ||
| Studio 369 | 12-Mar-2024 | Early Stage VC | Entertainment Software | ||
| Cirina | 31-May-2017 | Merger/Acquisition | Other Devices and Supplies |
GRAIL ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.49 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
GRAIL FAQs
-
When was GRAIL founded?
GRAIL was founded in 2015.
-
Where is GRAIL headquartered?
GRAIL is headquartered in Menlo Park, CA.
-
What is the size of GRAIL?
GRAIL has 910 total employees.
-
What industry is GRAIL in?
GRAIL’s primary industry is Biotechnology.
-
Is GRAIL a private or public company?
GRAIL is a Public company.
-
What is GRAIL’s stock symbol?
The ticker symbol for GRAIL is GRAL.
-
What is the current stock price of GRAIL?
As of 13-Nov-2026 the stock price of GRAIL is $115.89.
-
What is the current market cap of GRAIL?
The current market capitalization of GRAIL is $5.21B.
-
What is GRAIL’s current revenue?
The trailing twelve month revenue for GRAIL is $167M.
-
Who are GRAIL’s competitors?
Inovio Pharmaceuticals, GeneCast Biotechnology, Agomab Therapeutics, Fore Biotherapeutics, and Cardiff Oncology are some of the 22 competitors of GRAIL.
-
What is GRAIL’s annual earnings per share (EPS)?
GRAIL’s EPS for 12 months was -$9.28.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
